YieldMax COIN Option Income Strategy ETF vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? YieldMax COIN Option Income Strategy ETF trades at $18.68 (market cap $370.88M), while Royalty Pharma plc Class A Ordinary Shares trades at $56.2 (market cap $25.27B). The key difference: Royalty Pharma plc Class A Ordinary Shares is far larger — about 68.1× YieldMax COIN Option Income Strategy ETF's market cap, and Royalty Pharma plc Class A Ordinary Shares pays a 1.66% dividend while YieldMax COIN Option Income Strategy ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold YieldMax COIN Option Income Strategy ETF for 41 Days and Royalty Pharma plc Class A Ordinary Shares for 0 Days on average.
| CONY | RPRX | |
|---|---|---|
Market Cap | $370.88M | $25.27B |
Volume | 595,904 | 3,671,183 |
Sector | Income / Options Overlay | Health |
52-Week High | $76.50 | $63.96 |
52-Week Low | $17.73 | $35.44 |
Typical Hold Time | 41 Days | 0 Days |
Enterprise Value | — | $32.50B |
Dividend Yield | — | 1.66% |
Signals from Pluang's Aura AI — not financial advice
CONY trades at $19.16, down 3.38% today, with a bearish technical outlook as moving averages signal selling pressure. The ETF maintains weekly dividend distributions but faces structural NAV erosion concerns. Recent news highlights regulatory uncertainty impacting crypto-related stocks after Senate cryptocurrency legislation failed to advance.
The outlook remains challenging with significant YTD price decline and ongoing NAV decay despite high distribution rates. Investment opportunity exists for income-focused investors seeking weekly dividends, but structural risks and crypto market volatility present substantial downside exposure.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
CONY is an actively managed ETF that seeks to generate weekly income by selling call options on Coinbase (COIN) stock. It aims to provide high yield while maintaining exposure to the price movements of the crypto exchange.
Read more on CONY →Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →